Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: Preliminary report

被引:66
作者
Shipkova, M
Armstrong, VW
Kuypers, D
Perner, F
Fabrizi, V
Holzer, H
Wieland, E
Oellerich, M
机构
[1] Univ Gottingen, Bereich Humanmed, Klin Chem Abt, Dept Clin Chem, D-37075 Gottingen, Germany
[2] Univ Hosp Gasthuisberg, Dept Nephrol, B-3000 Louvain, Belgium
[3] Semmelweis Univ, Transplantat & Surg Clin, H-1085 Budapest, Hungary
[4] Univ Vienna, Dept Nephrol & Dialysis, Vienna, Austria
[5] Graz Univ, Med Clin, Dept Nephrol, Graz, Austria
关键词
mycophenolic acid; cyclosporin; drug interaction; mycophenolic acid pharmacokinetics; kidney transplantation;
D O I
10.1097/00007691-200112000-00020
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Mycophenolic acid (MPA) concentrations are lower in transplant recipients receiving mycophenolate mofetil (MMF) and cyclosporine compared with MMF with tacrolimus. It is not clear whether this is due to an effect of cyclosporin or tacrolimus on MPA pharmacokinetics. To study this effect, kidney transplant recipients with deteriorating renal function (n = 5) receiving cyclosporin and steroids were given mycophenolate mofetil over 4 weeks during a run-in phase (1 g/d in week 1, 1.5 g/d in week 2, 2 g/d starting from week 3). From week 5 the cyclosporin dose was reduced, and it was completely withdrawn at week 10. Creatinine, MPA, and MPA glucuronide metabolites (MPAG, AcMPAG) were determined before (week 4) and after (week 1 I and week 32) cyclosporin was withdrawn. Cyclosporin withdrawal was associated with increased MPA areas under the curve (AUCs) and predose concentrations in four of the five patients. In contrast, MPAG and AcMPAG AUCs as well as predose MPAG concentrations significantly decreased. Six months after cyclosporin withdrawal, MPA AUC and predose values tended to return to initial values, whereas metabolite concentrations remained low. Cyclosporin discontinuation caused an acute increase in MPA exposure and a concomitant reduction in metabolite concentrations. The results are consistent with the hypothesis that cyclosporin attenuates the enterohepatic recirculation of MPAG/MPA.
引用
收藏
页码:717 / 721
页数:5
相关论文
共 17 条
[1]  
Bullingham RES, 1996, TRANSPLANT P, V28, P925
[2]   Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression [J].
Filler, G ;
Zimmering, M ;
Mai, I .
PEDIATRIC NEPHROLOGY, 2000, 14 (02) :100-104
[3]  
Gregoor PJHS, 1999, TRANSPLANTATION, V68, P1603
[4]   The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation [J].
Hale, MD ;
Nicholls, AJ ;
Bullingham, RES ;
Hené, R ;
Hoitsma, A ;
Squifflet, JP ;
Weimar, W ;
Vanrenterghem, Y ;
Van de Woude, FJ ;
Verpooten, GA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (06) :672-683
[5]   Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients [J].
Hübner, GI ;
Eismann, R ;
Sziegoleit, W .
THERAPEUTIC DRUG MONITORING, 1999, 21 (05) :536-539
[6]   Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2 [J].
Kamisako, T ;
Leier, I ;
Cui, YH ;
König, J ;
Buchholz, U ;
Hummel-Eisenbeiss, J ;
Keppler, D .
HEPATOLOGY, 1999, 30 (02) :485-490
[7]   Hepatic secretion of conjugated drugs and endogenous substances [J].
Keppler, D ;
König, J .
SEMINARS IN LIVER DISEASE, 2000, 20 (03) :265-272
[8]   ABC drug transporters:: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2 [J].
Kerb, R ;
Hoffmeyer, S ;
Brinkmann, U .
PHARMACOGENOMICS, 2001, 2 (01) :51-64
[9]   The use of mycophenolate mofetil in transplant recipients [J].
Mele, TS ;
Halloran, PF .
IMMUNOPHARMACOLOGY, 2000, 47 (2-3) :215-245
[10]   Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil [J].
Shipkova, M ;
Armstrong, VW ;
Wieland, E ;
Niedmann, PD ;
Schütz, E ;
Brenner-Weiss, G ;
Voihsel, M ;
Braun, F ;
Oellerich, M .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (05) :1075-1082